SHAREHOLDER ALERT: The Law Offices of Vincent Wong Remind Aldeyra Investors of a Lead Plaintiff Deadline of September 29, 2023
Werte in diesem Artikel
NEW YORK, Sept. 11, 2023 /PRNewswire/ -- Attention Aldeyra Therapeutics, Inc. ("Aldeyra") (NASDAQ: ALDX) shareholders:
The Law Offices of Vincent Wong announce that a class action lawsuit has commenced on behalf of investors who purchased between March 17, 2022 and June 20, 2023.
If you suffered a loss on your investment in Aldeyra, contact us about potential recovery by using the link below. There is no cost or obligation to you.
https://www.wongesq.com/pslra-1/aldeyra-class-action-submission-form/?prid=47248&wire=4
ABOUT THE ACTION: The class action against Aldeyra includes allegations that the Company made materially false and/or misleading statements and/or failed to disclose that: (i) the ADX-2191 new drug application ("NDA") did not include adequate and well-controlled investigations and thus failed to show substantial evidence of ADX-2191's effectiveness; (ii) as a result, the FDA was unlikely to approve the ADX-2191 NDA in its current form; (iii) accordingly, the Company had overstated ADX-2191's clinical and/or commercial prospects; and (iv) as a result, the Company's public statements were materially false and misleading at all relevant times.
DEADLINE: September 29, 2023
Aggrieved Aldeyra investors only have until September 29, 2023 to request that the Court appoint you as lead plaintiff. You are not required to act as a lead plaintiff in order to share in any recovery.
Vincent Wong, Esq. is an experienced attorney who has represented investors in securities litigations involving financial fraud and violations of shareholder rights. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT:
Vincent Wong, Esq.
39 East Broadway
Suite 304
New York, NY 10002
Tel. 212.425.1140
E-Mail: vw@wongesq.com
View original content:https://www.prnewswire.com/news-releases/shareholder-alert-the-law-offices-of-vincent-wong-remind-aldeyra-investors-of-a-lead-plaintiff-deadline-of-september-29-2023-301922399.html
SOURCE The Law Offices of Vincent Wong
Ausgewählte Hebelprodukte auf Aldeyra Therapeutics
Mit Knock-outs können spekulative Anleger überproportional an Kursbewegungen partizipieren. Wählen Sie einfach den gewünschten Hebel und wir zeigen Ihnen passende Open-End Produkte auf Aldeyra Therapeutics
Der Hebel muss zwischen 2 und 20 liegen
Aktuelle Aldeyra Therapeutics Aktie News
Aldeyra Therapeutics Analysen
Um die Übersicht zu verbessern, haben Sie die Möglichkeit, die Analysen für Aldeyra Therapeutics nach folgenden Kriterien zu filtern.
Alle: Alle Empfehlungen
| Datum | Rating | Analyst | |
|---|---|---|---|
| 26.09.18 | Aldexa Therapeutics Overweight | Cantor Fitzgerald | |
| 26.01.18 | Aldexa Therapeutics Buy | Seaport Global Securities | |
| 26.09.16 | Aldexa Therapeutics Buy | H.C. Wainwright & Co. | |
| 01.07.16 | Aldexa Therapeutics Buy | Stifel, Nicolaus & Co., Inc. | |
| 01.07.15 | Aldexa Therapeutics Buy | Canaccord Adams |